BioNTech Looks To AI Partnership To Accelerate Drug Discovery
Cancer And Infectious Disease Pipeline Could Benefit
The German biotech has developed its COVID-19 vaccine in record-breaking time, but artificial intelligence could help accelerate drug discovery over the longer term.
You may also be interested in...
US FDA will hold 10 December advisory committee on Pfizer/BioNTech's just-filed application; the WHO issued a recommendation against Gilead's Veklury for hospitalized patients.
After years of setbacks, Novavax is on the cusp of success with its COVID-19 vaccine - but a rapid scale up of manufacturing and commercial operations will be a huge challenge.
Companies will raise their COVID-19 vaccine prices once the pandemic is over – but key long-term data will determine which comes out on top.